Zhou Zhengcan, Shang Ting, Li Xiurong, Zhu Hongyan, Qi Yu-Bo, Zhao Xin, Chen Xi, Shi Zhe-Xin, Pan Guixiang, Wang Yue-Fei, Fan Guanwei, Gao Xiumei, Zhu Yan, Feng Yuxin
State Key Laboratory of Component-based Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Research and Development Center of TCM, Tianjin International Joint Academy of Biotechnology and Medicine, Tianjin, China.
Front Physiol. 2021 Feb 12;11:608279. doi: 10.3389/fphys.2020.608279. eCollection 2020.
Acute gut graft-versus-host disease (aGVHD) is a leading threat to the survival of allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients. Abnormal gut microbiota is correlated with poor prognosis in allo-HSCT recipients. A disrupted intestinal microenvironment exacerbates dysbiosis in GVHD patients. We hypothesized that maintaining the integrity of the intestinal barrier may protect gut microbiota and attenuate aGVHD. This hypothesis was tested in a murine aGVHD model and an intestinal epithelial culture. Millipore cytokine array was utilized to determine the expression of proinflammatory cytokines in the serum. The 16S rRNA sequencing was used to determine the abundance and diversity of gut microbiota. Combining Xuebijing injection (XBJ) with a reduced dose of cyclosporine A (CsA) is superior to CsA alone in improving the survival of aGVHD mice and delayed aGVHD progression. This regimen also reduced interleukin 6 (IL-6) and IL-12 levels in the peripheral blood. 16S rRNA analysis revealed the combination treatment protected gut microbiota in aGVHD mice by reversing the dysbiosis at the phylum, genus, and species level. It inhibited enterococcal expansion, a hallmark of GVHD progression. It inhibited enterococcal expansion, a hallmark of GVHD progression. Furthermore, expansion was inhibited by this regimen. Pathology analysis revealed that the combination treatment improved the integrity of the intestinal tissue of aGVHD mice. It also reduced the intestinal permeability in aGVHD mice. Besides, XBJ ameliorated doxorubicin-induced intestinal epithelial death in CCK-8 assay. Overall, combining XBJ with CsA protected the intestinal microenvironment to prevent aGVHD. Our findings suggested that protecting the intestinal microenvironment could be a novel strategy to manage aGVHD. Combining XBJ with CsA may reduce the side effects of current aGVHD prevention regimens and improve the quality of life of allo-HSCT recipients.
急性肠道移植物抗宿主病(aGVHD)是异基因造血干细胞移植(allo-HSCT)受者生存的主要威胁。肠道微生物群异常与allo-HSCT受者的不良预后相关。肠道微环境紊乱会加剧GVHD患者的生态失调。我们假设维持肠道屏障的完整性可能保护肠道微生物群并减轻aGVHD。该假设在小鼠aGVHD模型和肠道上皮培养中进行了验证。利用密理博细胞因子阵列测定血清中促炎细胞因子的表达。采用16S rRNA测序确定肠道微生物群的丰度和多样性。在改善aGVHD小鼠的生存率和延缓aGVHD进展方面,血必净注射液(XBJ)与低剂量环孢素A(CsA)联合使用优于单独使用CsA。该方案还降低了外周血中白细胞介素6(IL-6)和IL-12水平。16S rRNA分析显示,联合治疗通过在门、属和种水平上逆转生态失调来保护aGVHD小鼠的肠道微生物群。它抑制了肠球菌的扩张,这是GVHD进展的一个标志。此外,该方案抑制了肠球菌的扩张。病理学分析显示,联合治疗改善了aGVHD小鼠肠道组织的完整性。它还降低了aGVHD小鼠的肠道通透性。此外,在CCK-8试验中,XBJ改善了阿霉素诱导的肠道上皮死亡。总体而言,XBJ与CsA联合使用可保护肠道微环境以预防aGVHD。我们的研究结果表明,保护肠道微环境可能是管理aGVHD的一种新策略。XBJ与CsA联合使用可能会减少当前aGVHD预防方案的副作用,并提高allo-HSCT受者的生活质量。